CagriSema mechanism of action combines amylin and GLP-1 receptor signaling to reduce appetite, slow gastric emptying, and drive weight loss in trials.
CagriSema works by activating two satiety hormone pathways at once: cagrilintide mimics amylin at amylin receptors, while semaglutide activates GLP-1 receptors. The combination slows gastric emptying, quiets appetite signaling in the brain, and improves blood sugar handling, which is why it has produced greater weight loss than either molecule alone. CagriSema is not approved by the FDA for human use as of early 2025.
What Is CagriSema?
CagriSema is an investigational once-weekly subcutaneous injection developed by Novo Nordisk. It pairs cagrilintide 2.4 mg, a long-acting amylin analog, with semaglutide 2.4 mg, the GLP-1 receptor agonist marketed as Wegovy.
The product is being studied for chronic weight management and type 2 diabetes under the REDEFINE clinical program. It is a fixed-dose combination, so both molecules arrive in a single injection rather than as two separate prescriptions.
The Two Receptor Pathways Behind CagriSema
The CagriSema mechanism of action starts with the two natural hormones the drug imitates. Amylin and GLP-1 are both gut- and pancreas-derived signals that tell the brain the body has had enough food.
Cagrilintide and Amylin Receptor Signaling
Amylin is co-released with insulin by pancreatic beta cells after a meal. Cagrilintide is an engineered analog that binds amylin receptors — calcitonin receptor complexes paired with RAMP proteins — in the hindbrain and area postrema.
Activation of those receptors promotes meal-ending satiety, slows stomach emptying, and suppresses glucagon. Natural amylin clears within minutes, but cagrilintide is modified to last about a week, which is what makes weekly dosing possible.
Semaglutide and GLP-1 Receptor Signaling
Semaglutide binds the GLP-1 receptor, the same target as the body's own incretin hormone. GLP-1 receptors sit on appetite-regulating neurons in the hypothalamus and brainstem.
Stimulation reduces hunger, slows gastric emptying, and increases glucose-dependent insulin release while lowering glucagon output. Semaglutide is also chemically stabilized against DPP-4 breakdown, giving it a roughly seven-day half-life.
How Does CagriSema Work in the Body?
The two components overlap in some effects and complement each other in others. That overlap is one reason researchers describe the pairing as additive-to-synergistic rather than redundant. Key physiological effects include:
- Central appetite suppression: both molecules act on brainstem and hypothalamic circuits that govern hunger and fullness.
- Slower gastric emptying: food leaves the stomach more gradually, extending the feeling of fullness after meals.
- Lower glucagon and better insulin response: amylin and GLP-1 signaling both help restrain post-meal glucose spikes.
- Reduced energy intake: participants in trials consistently report eating less without deliberate restriction.
Because amylin and GLP-1 receptors are distributed differently in the brain, the combination reaches appetite-control pathways that a GLP-1 agonist alone does not fully engage.
Cagrilintide vs. Semaglutide vs. CagriSema
| Agent | Primary target | Main physiological effect | Role in the combination |
|---|---|---|---|
| Cagrilintide 2.4 mg | Amylin receptors (calcitonin receptor plus RAMP) | Satiety, slower gastric emptying, glucagon suppression | Adds amylin-pathway appetite control |
| Semaglutide 2.4 mg | GLP-1 receptor | Central appetite suppression, glucose-dependent insulin release | Adds incretin signaling and glycemic benefit |
| CagriSema (fixed dose) | Both receptor families | Layered satiety and metabolic effects | Two pathways addressed in one weekly injection |
What the Clinical Trials Show
In the REDEFINE 1 phase 3 trial, adults with obesity or overweight plus at least one comorbidity lost an average of 22.7% of their body weight after 68 weeks on CagriSema. That result was roughly double the weight loss seen with semaglutide 2.4 mg or cagrilintide 2.4 mg given alone.
REDEFINE 2 tested the combination in adults with type 2 diabetes and excess weight, where blood sugar control is an additional endpoint. Novo Nordisk has said it intends to pursue regulatory approval, but no agency has cleared CagriSema for sale.
Dosing follows a slow escalation schedule to limit gastrointestinal upset. In trials, only about 57% of participants reached the full 2.4 mg/2.4 mg dose, largely because of nausea and vomiting during titration.
Safety, Tolerability, and Realistic Expectations
Because both components act on gut and brain pathways, the side effect profile resembles existing GLP-1 and amylin therapies. Commonly reported effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions, and they tend to be worst during dose escalation.
Anyone comparing prescription options should also review the side effects of lipo c injections and the side effects of acetyl-l-carnitine, since unregulated fat-loss products are frequently marketed alongside legitimate incretin drugs. CagriSema itself remains investigational, so it should only be used inside a clinical trial or a supervised program.
People exploring research compounds for metabolic goals often read up on the benefits of aod 9604 peptide, the benefits of l carnitine for men, and the cost of cjc-1295 ipamorelin. Those compounds work through entirely different biology and are not substitutes for CagriSema.
Talk with a licensed healthcare professional before starting, stopping, or combining any weight-management drug. Individual responses vary widely, and trial averages do not predict what any single person will experience.
Frequently Asked Questions
How does CagriSema work?
CagriSema pairs cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist. Both components reduce appetite and slow gastric emptying, but they act on different receptor families in the brainstem and hypothalamus. That dual action is why the combination has produced more weight loss than either drug alone in phase 3 trials.
Is CagriSema FDA approved?
No. As of early 2025, CagriSema is an investigational product and has not been approved by the FDA or any other regulatory agency. It is available only through clinical trials. Novo Nordisk has stated that it plans to seek approval, but no review has been completed.
What is the difference between CagriSema and semaglutide?
Semaglutide targets only the GLP-1 receptor, while CagriSema adds cagrilintide, which targets amylin receptors. In the REDEFINE 1 trial, CagriSema produced about 22.7% average weight loss at 68 weeks, roughly double the result seen with semaglutide 2.4 mg alone. The tradeoff is that CagriSema is not yet approved or commercially available.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.